178 related articles for article (PubMed ID: 28408526)
21. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and preliminary biological evaluation of O-2((2-[(18)F]fluoroethyl)methylamino)ethyltyrosine ([(18)F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging.
Chiotellis A; Müller A; Weyermann K; Leutwiler DS; Schibli R; Ametamey SM; Krämer SD; Mu L
Amino Acids; 2014 Aug; 46(8):1947-59. PubMed ID: 24802247
[TBL] [Abstract][Full Text] [Related]
23. Superscan pattern of F-18 sodium fluoride PET/CT study in a case of prostate cancer.
Li Y; Tafti BA; Shaba W; Berenji GR
Clin Nucl Med; 2011 Nov; 36(11):1046-8. PubMed ID: 21975402
[No Abstract] [Full Text] [Related]
24. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
25.
Liu C; Liu T; Zhang N; Liu Y; Li N; Du P; Yang Y; Liu M; Gong K; Yang X; Zhu H; Yan K; Yang Z
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1852-1861. PubMed ID: 29717333
[TBL] [Abstract][Full Text] [Related]
26. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
McEwan LM; Wong D; Yaxley J
J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
[TBL] [Abstract][Full Text] [Related]
27. Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer.
Petersen LJ; Zacho HD
Scand J Urol; 2017 Dec; 51(6):498-501. PubMed ID: 28748722
[No Abstract] [Full Text] [Related]
28. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
29. PET for prostate cancer imaging: still a quandary or the ultimate solution?
Kotzerke J; Gschwend JE; Neumaier B
J Nucl Med; 2002 Feb; 43(2):200-2. PubMed ID: 11850484
[No Abstract] [Full Text] [Related]
30. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography.
Sanchez-Crespo A
Appl Radiat Isot; 2013 Jun; 76():55-62. PubMed ID: 23063597
[TBL] [Abstract][Full Text] [Related]
31.
Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous
Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
[TBL] [Abstract][Full Text] [Related]
33. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
34. Dynamic infrared imaging of newly diagnosed malignant lymphoma compared with Gallium-67 and Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography.
Janicek MJ; Demetri G; Janicek MR; Shaffer K; Fauci MA
Technol Cancer Res Treat; 2003 Dec; 2(6):571-8. PubMed ID: 14640768
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
36. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
37.
Eiber M; Herrmann K; Fendler WP; Maurer T
Eur Urol; 2016 Dec; 70(6):938-940. PubMed ID: 27481174
[No Abstract] [Full Text] [Related]
38. Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
Skovgaard D; Persson M; Kjaer A
PET Clin; 2017 Apr; 12(2):243-255. PubMed ID: 28267457
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous whole-body
Freitag MT; Kesch C; Cardinale J; Flechsig P; Floca R; Eiber M; Bonekamp D; Radtke JP; Kratochwil C; Kopka K; Hohenfellner M; Stenzinger A; Schlemmer HP; Haberkorn U; Giesel F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):340-347. PubMed ID: 29038888
[TBL] [Abstract][Full Text] [Related]
40. Lymphangitic Carcinomatosis From Prostate Cancer Identified With Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography Imaging.
Tang VD; Campbell P; Pattison DA
Urology; 2018 Apr; 114():e1-e2. PubMed ID: 29291425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
